Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)
Condition(s):Biliary Tract Cancer; Gemox ChemotherapyLast Updated:March 20, 2024Recruiting
Include Studies Not Open or Pending
Condition(s):Biliary Tract Cancer; Gemox ChemotherapyLast Updated:March 20, 2024Recruiting
Condition(s):Carcinoma; Non-Small-Cell Lung Cancer; AdenocarcinomaLast Updated:December 27, 2023Recruiting
Condition(s):Lung Cancer, Non-small Cell; EGFR Gene Mutation; EGFR-TKI Resistant Mutation; Primary Resistance; Circulating Tumor DNALast Updated:August 2, 2023Recruiting
Condition(s):Different Gene Between Different TKIs EffectionLast Updated:April 12, 2022Recruiting
Condition(s):Non Small Cell Lung CancerLast Updated:March 12, 2024Not yet recruiting
Condition(s):Oligometastatic Disease; Non-small Cell Lung Cancer; Driver MutationLast Updated:April 12, 2023Recruiting
Condition(s):Neovascular Age-Related Macular DegenerationLast Updated:February 13, 2024Recruiting
Condition(s):Stage IIIA Hepatocellular CarcinomaLast Updated:September 29, 2023Not yet recruiting
Condition(s):Gastro-intestinal Stromal TumorLast Updated:October 11, 2023Recruiting
Condition(s):Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors; ERBB2 Gene Duplication; Disitamab VedotinLast Updated:December 29, 2023Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.